Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 06 September, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 526269 | NSE: CRSTCHM

Crestchem Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 6, 2025, 12:22 am

Market Cap 35.7 Cr.
Current Price 119
High / Low 350/114
Stock P/E14.4
Book Value 24.9
Dividend Yield0.84 %
ROCE59.9 %
ROE44.1 %
Face Value 10.0
PEG Ratio0.42

Quick Insight

Crestchem Ltd, operating in the organic chemicals industry, presents an intriguing investment opportunity with a current share price of ₹122 and a market capitalization of ₹36.7 Cr. The company's financial metrics further bolster its attractiveness, with a modest P/E ratio of 14.8, a robust ROE of 44.1%, and an impressive ROCE of 59.9%. Additionally, Crestchem boasts a healthy operating profit margin of 7.16% and a solid interest coverage ratio of 286.32x, indicating strong financial health. With zero borrowings, ample reserves of ₹4.48 Cr, and a comfortable CCC of 37.41 days, Crestchem appears well-positioned for sustainable growth and value creation. Investors should closely monitor this stock for potential long-term gains in the organic chemicals sector.

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Crestchem Ltd

Competitors of Crestchem Ltd

Stock Name Market Cap Current Price High / Low Stock P/E Book Value Dividend Yield ROCE ROE Face Value
Gujchem Distillers India Ltd 140 Cr. 391 541/255144 3900.00 %0.22 %0.10 % 1.00
Elantas Beck India Ltd 8,512 Cr. 10,738 14,980/8,15064.0 1,1770.07 %23.0 %17.4 % 10.0
Crestchem Ltd 35.7 Cr. 119 350/11414.4 24.90.84 %59.9 %44.1 % 10.0
Chemiesynth (Vapi) Ltd 11.0 Cr. 35.8 35.8/0.00 35.80.00 %2.99 %0.99 % 10.0
Archit Organosys Ltd 97.4 Cr. 47.5 53.5/34.216.0 33.71.05 %10.8 %7.57 % 10.0
Industry Average5,106.15 Cr1,911.8058.71341.080.36%14.37%10.47%7.41

All Competitor Stocks of Crestchem Ltd

Quarterly Result

MetricJun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
Sales 4.803.895.172.873.784.497.365.635.257.804.807.235.03
Expenses 4.633.744.712.833.514.086.134.784.496.534.156.634.67
Operating Profit 0.170.150.460.040.270.411.230.850.761.270.650.600.36
OPM % 3.54%3.86%8.90%1.39%7.14%9.13%16.71%15.10%14.48%16.28%13.54%8.30%7.16%
Other Income 0.030.030.030.050.050.060.060.090.080.120.090.140.13
Interest 0.000.000.000.000.000.000.000.000.000.000.000.000.00
Depreciation 0.000.010.010.010.000.010.010.010.010.010.010.020.02
Profit before tax 0.200.170.480.080.320.461.280.930.831.380.730.720.47
Tax % 25.00%23.53%27.08%12.50%25.00%26.09%28.91%27.96%27.71%28.26%27.40%15.28%25.53%
Net Profit 0.140.120.360.070.240.340.910.660.601.000.520.610.35
EPS in Rs 0.470.401.200.230.801.133.032.202.003.331.732.031.17

Last Updated: August 19, 2025, 8:35 pm

Below is a detailed analysis of the quarterly data for Crestchem Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

  • For Sales, as of Jun 2025, the value is 5.03 Cr.. The value appears to be declining and may need further review. It has decreased from 7.23 Cr. (Mar 2025) to 5.03 Cr., marking a decrease of 2.20 Cr..
  • For Expenses, as of Jun 2025, the value is 4.67 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.63 Cr. (Mar 2025) to 4.67 Cr., marking a decrease of 1.96 Cr..
  • For Operating Profit, as of Jun 2025, the value is 0.36 Cr.. The value appears to be declining and may need further review. It has decreased from 0.60 Cr. (Mar 2025) to 0.36 Cr., marking a decrease of 0.24 Cr..
  • For OPM %, as of Jun 2025, the value is 7.16%. The value appears to be declining and may need further review. It has decreased from 8.30% (Mar 2025) to 7.16%, marking a decrease of 1.14%.
  • For Other Income, as of Jun 2025, the value is 0.13 Cr.. The value appears to be declining and may need further review. It has decreased from 0.14 Cr. (Mar 2025) to 0.13 Cr., marking a decrease of 0.01 Cr..
  • For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
  • For Depreciation, as of Jun 2025, the value is 0.02 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.02 Cr..
  • For Profit before tax, as of Jun 2025, the value is 0.47 Cr.. The value appears to be declining and may need further review. It has decreased from 0.72 Cr. (Mar 2025) to 0.47 Cr., marking a decrease of 0.25 Cr..
  • For Tax %, as of Jun 2025, the value is 25.53%. The value appears to be increasing, which may not be favorable. It has increased from 15.28% (Mar 2025) to 25.53%, marking an increase of 10.25%.
  • For Net Profit, as of Jun 2025, the value is 0.35 Cr.. The value appears to be declining and may need further review. It has decreased from 0.61 Cr. (Mar 2025) to 0.35 Cr., marking a decrease of 0.26 Cr..
  • For EPS in Rs, as of Jun 2025, the value is 1.17. The value appears to be declining and may need further review. It has decreased from 2.03 (Mar 2025) to 1.17, marking a decrease of 0.86.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 8:03 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 0.420.090.130.140.050.106.157.627.9016.6621.1824.9824.86
Expenses 0.360.230.180.340.290.265.596.957.1515.8418.4021.6621.98
Operating Profit 0.06-0.14-0.05-0.20-0.24-0.160.560.670.750.822.783.322.88
OPM % 14.29%-155.56%-38.46%-142.86%-480.00%-160.00%9.11%8.79%9.49%4.92%13.13%13.29%11.58%
Other Income 0.030.890.190.080.030.020.030.050.080.150.260.440.48
Interest 0.030.020.020.040.010.010.000.020.020.010.010.050.00
Depreciation 0.080.050.000.000.000.010.020.020.030.020.050.050.06
Profit before tax -0.020.680.12-0.16-0.22-0.160.570.680.780.942.983.663.30
Tax % 0.00%10.29%25.00%0.00%-13.64%0.00%22.81%14.71%26.92%26.60%27.85%25.41%
Net Profit -0.030.610.09-0.16-0.19-0.170.440.570.570.692.152.732.48
EPS in Rs -0.102.030.30-0.53-0.63-0.571.471.901.902.307.179.108.26
Dividend Payout % 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%6.98%10.99%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)2133.33%-85.25%-277.78%-18.75%10.53%358.82%29.55%0.00%21.05%211.59%26.98%
Change in YoY Net Profit Growth (%)0.00%-2218.58%-192.53%259.03%29.28%348.30%-329.28%-29.55%21.05%190.54%-184.62%

Crestchem Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:76%
5 Years:32%
3 Years:47%
TTM:9%
Compounded Profit Growth
10 Years:34%
5 Years:44%
3 Years:69%
TTM:-1%
Stock Price CAGR
10 Years:28%
5 Years:43%
3 Years:42%
1 Year:-26%
Return on Equity
10 Years:35%
5 Years:44%
3 Years:45%
Last Year:44%

Last Updated: September 5, 2025, 3:06 pm

Balance Sheet

Last Updated: August 11, 2025, 3:43 pm

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital 3.003.003.003.003.003.003.003.003.003.003.003.00
Reserves -2.59-2.09-2.00-2.16-2.36-2.53-2.08-1.51-0.94-0.251.904.48
Borrowings 0.400.370.350.600.140.280.020.630.270.000.000.00
Other Liabilities 0.490.220.050.050.040.141.350.870.962.042.243.07
Total Liabilities 1.301.501.401.490.820.892.292.993.294.797.1410.55
Fixed Assets 0.460.040.040.040.110.120.100.140.110.100.170.26
CWIP 0.000.000.000.000.000.000.000.000.000.000.000.00
Investments 0.000.000.000.000.000.000.000.000.000.000.000.00
Other Assets 0.841.461.361.450.710.772.192.853.184.696.9710.29
Total Assets 1.301.501.401.490.820.892.292.993.294.797.1410.55

Below is a detailed analysis of the balance sheet data for Crestchem Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Mar 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.00 Cr..
  • For Reserves, as of Mar 2025, the value is 4.48 Cr.. The value appears strong and on an upward trend. It has increased from 1.90 Cr. (Mar 2024) to 4.48 Cr., marking an increase of 2.58 Cr..
  • For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
  • For Other Liabilities, as of Mar 2025, the value is 3.07 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.24 Cr. (Mar 2024) to 3.07 Cr., marking an increase of 0.83 Cr..
  • For Total Liabilities, as of Mar 2025, the value is 10.55 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.14 Cr. (Mar 2024) to 10.55 Cr., marking an increase of 3.41 Cr..
  • For Fixed Assets, as of Mar 2025, the value is 0.26 Cr.. The value appears strong and on an upward trend. It has increased from 0.17 Cr. (Mar 2024) to 0.26 Cr., marking an increase of 0.09 Cr..
  • For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
  • For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
  • For Other Assets, as of Mar 2025, the value is 10.29 Cr.. The value appears strong and on an upward trend. It has increased from 6.97 Cr. (Mar 2024) to 10.29 Cr., marking an increase of 3.32 Cr..
  • For Total Assets, as of Mar 2025, the value is 10.55 Cr.. The value appears strong and on an upward trend. It has increased from 7.14 Cr. (Mar 2024) to 10.55 Cr., marking an increase of 3.41 Cr..

Notably, the Reserves (4.48 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +-0.100.05-0.27-0.04-0.70-0.020.330.390.822.210.351.66
Cash from Investing Activity +0.020.060.340.640.120.01-0.35-0.39-0.83-1.34-1.07-0.99
Cash from Financing Activity +0.07-0.05-0.02-0.04-0.01-0.010.00-0.02-0.02-0.01-0.01-0.09
Net Cash Flow-0.010.060.050.55-0.58-0.02-0.02-0.01-0.020.86-0.720.59

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-0.34-0.51-0.40-0.80-0.38-0.440.540.040.480.822.783.32

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days356.310.00336.92469.29730.00292.0071.8167.5441.580.4426.3737.41
Inventory Days0.0060.830.0073.000.00182.500.750.000.000.000.000.00
Days Payable60.8373.00365.0091.06
Cash Conversion Cycle356.310.00336.92469.29730.00109.50-18.5067.5441.580.4426.3737.41
Working Capital Days-234.64-1,987.22-645.77-1,016.79438.00-292.003.5612.93-2.77-36.81-1.218.47
ROCE %1.30%-13.40%10.65%-8.60%-18.92%-19.61%67.46%45.75%35.96%37.40%78.17%59.94%

Financial Efficiency Indicators Chart

No data available for the Shareholding

No data available for the Shareholding Pattern chart.

No data available for the No. of Shareholders chart.

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 9.097.152.311.8919.91
Diluted EPS (Rs.) 9.097.152.311.8919.91
Cash EPS (Rs.) 9.267.312.391.981.99
Book Value[Excl.RevalReserv]/Share (Rs.) 24.9216.339.186.874.97
Book Value[Incl.RevalReserv]/Share (Rs.) 24.9216.339.186.874.97
Dividend / Share (Rs.) 1.000.500.000.000.00
Revenue From Operations / Share (Rs.) 83.5970.8555.7626.4925.47
PBDIT / Share (Rs.) 12.4110.113.232.742.38
PBIT / Share (Rs.) 12.239.963.162.662.30
PBT / Share (Rs.) 12.199.933.132.602.24
Net Profit / Share (Rs.) 9.097.152.311.891.91
PBDIT Margin (%) 14.8414.275.8010.359.33
PBIT Margin (%) 14.6314.055.6610.029.02
PBT Margin (%) 14.5814.015.609.828.81
Net Profit Margin (%) 10.8710.094.147.137.51
Return on Networth / Equity (%) 36.4743.8025.1827.5338.46
Return on Capital Employeed (%) 48.6260.5334.2638.5744.70
Return On Assets (%) 25.8530.0414.4817.2219.14
Total Debt / Equity (X) 0.000.000.000.120.42
Asset Turnover Ratio (%) 2.843.564.142.532.89
Current Ratio (X) 1.441.040.600.951.85
Quick Ratio (X) 1.441.040.600.951.85
Inventory Turnover Ratio (X) 0.000.0011553.392181.021235.35
Interest Coverage Ratio (X) 286.32430.2198.7552.2044.41
Interest Coverage Ratio (Post Tax) (X) 210.73305.4071.5636.9836.75
Enterprise Value (Cr.) 61.2534.0735.8612.567.51
EV / Net Operating Revenue (X) 2.441.602.141.580.98
EV / EBITDA (X) 16.4611.2336.9515.2610.53
MarketCap / Net Operating Revenue (X) 2.471.612.201.551.03
Price / BV (X) 8.296.9813.345.975.27
Price / Net Operating Revenue (X) 2.471.612.201.551.03
EarningsYield 0.040.060.010.040.07

After reviewing the key financial ratios for Crestchem Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 9.09. This value is within the healthy range. It has increased from 7.15 (Mar 24) to 9.09, marking an increase of 1.94.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 9.09. This value is within the healthy range. It has increased from 7.15 (Mar 24) to 9.09, marking an increase of 1.94.
  • For Cash EPS (Rs.), as of Mar 25, the value is 9.26. This value is within the healthy range. It has increased from 7.31 (Mar 24) to 9.26, marking an increase of 1.95.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 24.92. It has increased from 16.33 (Mar 24) to 24.92, marking an increase of 8.59.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 24.92. It has increased from 16.33 (Mar 24) to 24.92, marking an increase of 8.59.
  • For Dividend / Share (Rs.), as of Mar 25, the value is 1.00. This value is within the healthy range. It has increased from 0.50 (Mar 24) to 1.00, marking an increase of 0.50.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 83.59. It has increased from 70.85 (Mar 24) to 83.59, marking an increase of 12.74.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 12.41. This value is within the healthy range. It has increased from 10.11 (Mar 24) to 12.41, marking an increase of 2.30.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 12.23. This value is within the healthy range. It has increased from 9.96 (Mar 24) to 12.23, marking an increase of 2.27.
  • For PBT / Share (Rs.), as of Mar 25, the value is 12.19. This value is within the healthy range. It has increased from 9.93 (Mar 24) to 12.19, marking an increase of 2.26.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 9.09. This value is within the healthy range. It has increased from 7.15 (Mar 24) to 9.09, marking an increase of 1.94.
  • For PBDIT Margin (%), as of Mar 25, the value is 14.84. This value is within the healthy range. It has increased from 14.27 (Mar 24) to 14.84, marking an increase of 0.57.
  • For PBIT Margin (%), as of Mar 25, the value is 14.63. This value is within the healthy range. It has increased from 14.05 (Mar 24) to 14.63, marking an increase of 0.58.
  • For PBT Margin (%), as of Mar 25, the value is 14.58. This value is within the healthy range. It has increased from 14.01 (Mar 24) to 14.58, marking an increase of 0.57.
  • For Net Profit Margin (%), as of Mar 25, the value is 10.87. This value exceeds the healthy maximum of 10. It has increased from 10.09 (Mar 24) to 10.87, marking an increase of 0.78.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 36.47. This value is within the healthy range. It has decreased from 43.80 (Mar 24) to 36.47, marking a decrease of 7.33.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 48.62. This value is within the healthy range. It has decreased from 60.53 (Mar 24) to 48.62, marking a decrease of 11.91.
  • For Return On Assets (%), as of Mar 25, the value is 25.85. This value is within the healthy range. It has decreased from 30.04 (Mar 24) to 25.85, marking a decrease of 4.19.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 2.84. It has decreased from 3.56 (Mar 24) to 2.84, marking a decrease of 0.72.
  • For Current Ratio (X), as of Mar 25, the value is 1.44. This value is below the healthy minimum of 1.5. It has increased from 1.04 (Mar 24) to 1.44, marking an increase of 0.40.
  • For Quick Ratio (X), as of Mar 25, the value is 1.44. This value is within the healthy range. It has increased from 1.04 (Mar 24) to 1.44, marking an increase of 0.40.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 286.32. This value is within the healthy range. It has decreased from 430.21 (Mar 24) to 286.32, marking a decrease of 143.89.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 210.73. This value is within the healthy range. It has decreased from 305.40 (Mar 24) to 210.73, marking a decrease of 94.67.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 61.25. It has increased from 34.07 (Mar 24) to 61.25, marking an increase of 27.18.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.44. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 2.44, marking an increase of 0.84.
  • For EV / EBITDA (X), as of Mar 25, the value is 16.46. This value exceeds the healthy maximum of 15. It has increased from 11.23 (Mar 24) to 16.46, marking an increase of 5.23.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.47. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 2.47, marking an increase of 0.86.
  • For Price / BV (X), as of Mar 25, the value is 8.29. This value exceeds the healthy maximum of 3. It has increased from 6.98 (Mar 24) to 8.29, marking an increase of 1.31.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.47. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 2.47, marking an increase of 0.86.
  • For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.04, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Crestchem Ltd as of September 6, 2025 is: 127.56

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of September 6, 2025, Crestchem Ltd is Undervalued by 7.19% compared to the current share price 119.00

Intrinsic Value of Crestchem Ltd as of September 6, 2025 is: 171.14

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of September 6, 2025, Crestchem Ltd is Undervalued by 43.82% compared to the current share price 119.00

Last 5 Year EPS CAGR: 34.17%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 23.01%, which is a positive sign.
  2. The stock has a low average Working Capital Days of -62.69, which is a positive sign.
  3. The company has shown consistent growth in sales (8.48 cr) and profit (1.01 cr) over the years.
  1. The stock has a high average Cash Conversion Cycle of 179.74, which may not be favorable.
  2. The company has higher borrowings (0.26) compared to reserves (-1.01), which may suggest financial risk.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Crestchem Ltd:
    1. Net Profit Margin: 10.87%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 48.62% (Industry Average ROCE: 14.37%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 36.47% (Industry Average ROE: 10.47%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 210.73
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.44
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 14.4 (Industry average Stock P/E: 58.71)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Crestchem Ltd. is a Public Limited Listed company incorporated on 26/04/1991 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24100GJ1991PLC015530 and registration number is 015530. Currently Company is involved in the business activities of Manufacture of various other chemical products(antiknock preparations, anti-freeze preparations, liquids for hydraulic transmission, composite diagnostic or laboratory reagents, writing or drawing ink, chemical substance used in manufacturing of pesticides and other chemical products). Company's Total Operating Revenue is Rs. 25.08 Cr. and Equity Capital is Rs. 3.00 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Chemicals - Organic - OthersSr. No.550/1, Sub Plot Number 12, Mehsana Dist. Gujarat 382715info@crestchemlimited.in
http://www.crestchemlimited.in
Management
NamePosition Held
Mr. Dipak Narendraprasad PatelPromoter, Chairman & Managing Director
Mr. Nitinkumar Shantilal ShahNon Exe. & Ind. Director
Mrs. Rinkal Maulik JasaniNon Exe. Women Independent Director
Mrs. Priyankaben M PatelInd. Non-Executive Director
Mr. Jignesh A ShahInd. Non-Executive Director
Mr. Nirmit Dipak PatelExecutive Director

FAQ

What is the intrinsic value of Crestchem Ltd?

Crestchem Ltd's intrinsic value (as of 05 September 2025) is 127.56 which is 7.19% higher the current market price of 119.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹35.7 Cr. market cap, FY2025-2026 high/low of 350/114, reserves of ₹4.48 Cr, and liabilities of 10.55 Cr.

What is the Market Cap of Crestchem Ltd?

The Market Cap of Crestchem Ltd is 35.7 Cr..

What is the current Stock Price of Crestchem Ltd as on 05 September 2025?

The current stock price of Crestchem Ltd as on 05 September 2025 is 119.

What is the High / Low of Crestchem Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Crestchem Ltd stocks is 350/114.

What is the Stock P/E of Crestchem Ltd?

The Stock P/E of Crestchem Ltd is 14.4.

What is the Book Value of Crestchem Ltd?

The Book Value of Crestchem Ltd is 24.9.

What is the Dividend Yield of Crestchem Ltd?

The Dividend Yield of Crestchem Ltd is 0.84 %.

What is the ROCE of Crestchem Ltd?

The ROCE of Crestchem Ltd is 59.9 %.

What is the ROE of Crestchem Ltd?

The ROE of Crestchem Ltd is 44.1 %.

What is the Face Value of Crestchem Ltd?

The Face Value of Crestchem Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Crestchem Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE